TABLE 1.
Baseline characteristics.
| Baseline characteristics | CWD (N = 122) | FWD (N = 123) | p‐value |
|---|---|---|---|
| Age (years) – mean ± SD | 52.5 ± 14.7 | 53.7 ± 18.5 | 0.56 |
| Weight (kg) – mean ± SD | 92.5 ± 24.9 | 86.2 ± 25.9 | 0.05 |
| Height (cm) –mean ± SD | 168.2 ± 8.9 | 163.9 ± 9.8 | <0.001 |
| Body mass index (kg/m2)‐mean ± SD | 32.6 ± 8.2 | 31.9 ± 8.6 | 0.53 |
| Male (%) | 79 (65.6) | 55 (44.7) | 0.001 |
| Blacks (%) | 12 (10) | 16 (13) | 0.46 |
| Origin (%) | |||
| GCC & Yemen | 41 (33.6) | 39 (31.7) | 0.35 |
| Levant | 39 (32) | 32 (26) | |
| Egypt | 26 (21.3) | 26 (21.1) | |
| Sudan | 11 (9) | 16 (13) | |
| North Africa | 2 (1.6) | 7 (5.7) | |
| Other a | 3 (2.4) | 1 (0.8) | |
| Indication for anticoagulation (%) | |||
| AF | 22 (18) | 37 (30.1) | 0.001 |
| DVT | 25 (20.5) | 34 (27.6) | |
| PE | 19 (15.6) | 23 (18.7) | |
| Prosthetic valves | 5 (4.1) | 3 (2.4) | |
| LVT | 19 (15.6) | 2 (1.6) | |
| Other b | 32 (26.2) | 24 (19.5) | |
| Diabetes (%) | 52 (42.6) | 42 (34.1) | 0.17 |
| Hypertension (%) | 65 (53.3) | 61 (49.6) | 0.56 |
| Heart failure (%) | 16 (13.1) | 24 (19.5) | 0.18 |
| Coronary artery diseases (%) | 15 (12.3) | 33 (26.8) | 0.004 |
| Liver diseases (%) | 2 (1.6) | 0 (0) | 0.15 |
| Patients who smoke (%) | 30 (24.6) | 12 (9.8) | 0.002 |
| Patients who drink alcohol (%) | 2 (1.7) | 0 (0) | 0.15 |
| Interacting medications (%) c | 13 (10.8) | 15 (12.2) | 0.7 |
| Target INR other than 2–3 (%) | 0 (0) | 2 (1.6) | 0.16 |
| Anticoagulation duration (%) | |||
| 3 months | 23 (28.9) | 13 (10.6) | 0.2 |
| 6 months | 26 (21.3) | 26 (21.1) | |
| Undefined | 17 (13.9) | 14 (11.4) | |
| Life long | 56 (45.9) | 70 (56.9) | |
| Baseline INR‐mean ± SD | 1.1 ± 0.1 | 1.1 ± 0.1 | 0.94 |
| Received loading dose (%) | 45 (36.9) | 21 (17.1) | <0.001 |
| Daily warfarin dose (mg) – mean ± SD | 4.8 ± 2.4 | 4.9 ± 2.4 | 0.87 |
| Total warfarin days For TTR calculation‐mean ± SD | 31.8 ± 7.1 | 30.6 ± 5.1 | 0.11 |
| Initial day for TTR calculation – mean ± SD | 4.6 ± 0 0.96 | 4.8 ± 0.85 | 0.07 |
| Number of visits – mean ± SD | 9.1 ± 4.9 | 9.3 ± 4.5 | 0.93 |
Abbreviatons: AF, atrial fibrillation; DVT, deep vein thrombosis; GCC, Gulf council countries; INR, international normalized ratio; PE, pulmonary embolism; LV, left ventricular thrombus; SD, standard deviation; TTR, time in therapeutic range.
Other: Iraq, India.
Other: Cerebral vein thrombosis, portal vein thrombosis, mesenteric vein thrombosis, hepatic vein thrombosis, jugular vein thrombosis, renal vein thrombosis, peripheral vascular disease, LV non‐compaction, arterio‐venous fistula thrombosis, and atrial thrombosis).
Interacting medications: Any medication that interacts with warfarin and has a category higher than category C according to Lexicomp® interaction checker. (See Table S1 for details of interacting medication and their interaction category).